The boutique contract development and manufacturing organization (CDMO) Wheeler Bio has closed a $31 million Series A financing round, which it plans to use to complete a CGMP cell banking and drug substance manufacturing facility in Oklahoma City. The company specializes in process development and small batch CGMP production of therapeutic antibodies. Wheeler says the…